01053-X/asset/826330f0-5581-4d6d-8f45-2192fe6ac242/main.assets/gr2_lrg.jpg)
retatrutide case study Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Triple hormone receptor agonist retatrutide
Description
Fastest weight loss velocity occurs between weeks 12 and 24
Youve already been through enough
However, hair loss during GLP-1 therapy is multifactorial, and a supplement alone may not fully resolve it
This could diminish the unique advantage retatrutide holds over dual-agonists like tirzepatide
Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes
FDA-approved medications have extensive clinical trial data
